Bibliographic Details
| Title: |
Riluzole is associated with decreasing neuritic plaque severity in amyotrophic lateral sclerosis. |
| Authors: |
Mazumder, Srestha, McCann, Heather, D'Silva, Susan, Furlong, Sarah, Shepherd, Claire E, Kril, Jillian J, Halliday, Glenda M, Rowe, Dominic B, Kiernan, Matthew C, Tan, Rachel H |
| Source: |
Brain: A Journal of Neurology; Mar2023, Vol. 146 Issue 3, pe17-e19, 3p |
| Subject Terms: |
AMYLOID plaque, AMYOTROPHIC lateral sclerosis, CEREBRAL amyloid angiopathy, POSTMORTEM changes, RILUZOLE |
| Abstract: |
The glutamate modulator, riluzole, extends survival in amyotrophic lateral sclerosis (ALS) and was recently assessed in a clinical trial for Alzheimer's disease (Ad).[1] This trial found that riluzole-treated patients with Ad had a significantly reduced decline of cerebral glucose metabolism in multiple Ad predilection brain regions compared to placebo, which correlated with cognitive performance.[1] Importantly however, assessment of amyloid load was not included in the trial and as such, the effect of riluzole treatment on Ad neuropathological changes in patients remains to be clarified. The severity of neuritic plaques were graded according to the neuritic plaque score of (A) C1: sparse (1-5 neuritic plaques per mm2); (B) C2: moderate (>=6 neuritic plaques per mm2); and (C) C3: frequent (>=20 neuritic plaques per mm2). [Extracted from the article] |
|
Copyright of Brain: A Journal of Neurology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
